Microalgal Oil Supplementation Has an Anti-Obesity Effect in C57BL/6J Mice Fed a High Fat Diet.

Jin-Seon Yook^{1*}, Kyung-Ah Kim^{2*}, Jeong Eun Park¹, Seon-Hwa Lee¹, and Youn-Soo Cha¹

¹Department of Food Science and Human Nutrition, Brain Korea 21 Plus, Chonbuk National University, Jeonbuk 54896, Korea

²Department of Food and Nutrition, Songwon University, Gwanju 61756, Korea

ABSTRACT: This study investigated the impact of microalgal oil (MO) on body weight management in C57BL/6J mice. Obesity was induced for 8 weeks and animals were orally supplemented with the following for 8 additional weeks: beef tallow (BT), corn oil, fish oil (FO), microalgal oil (MO), or none, as a high fat diet control group (HD). A normal control group was fed with a normal diet. After completing the experiment, the FO and MO groups showed significant decreases in body weight gain, epididymal fat pad weights, serum triglycerides, and total cholesterol levels compared to the HD and BT groups. A lower mRNA expression level of lipid anabolic gene and higher levels of lipid catabolic genes were observed in both FO and MO groups. Serum insulin and leptin concentrations were lower in the MO group. These results indicated that microalgal oil has an anti-obesity effect that can combat high fat diet-induced obesity in mice.

Keywords: microalgae, omega-3, polyunsaturated fatty acids, lipid profile, obesity

INTRODUCTION

Omega-3 fatty acids, especially eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), are long-chain polyunsaturated fatty acids (PUFAs) that are used as health promoting supplements. Many studies have demonstrated protective effects of omega-3s against cardiovascular disease (1), cancer (2), atherosclerosis (3), and obesity (4). However, the omega-6/omega-3 ratio plays a critical role in the outcome; high amounts of omega-6 fatty acids have been shown to be associated with several diseases such as cardiovascular disease, cancer, inflammatory disease, and autoimmune disorders, while higher levels of omega-3 averts such negative effects (5).

Transitions in global dietary patterns are frequently observed and have been well documented. The preference for food preparation using vegetable oil has increased, leading to a higher portion of omega-6 fatty acids in the lipid pool (5,6).

The major sources for omega-3 PUFAs are marine fish and fish-based products. However, increased awareness of the benefits of omega-3 PUFAs has increased, along with the demand for fish and its oil. However, humans cannot depend only on fish-based products, as intensive fishing to meet the demand of fish oil will result in the

threat of extinction for many fish species. Moreover, fish oil also have disadvantages such as an unpleasant odor and danger of contaminants (e.g., methyl-mercury, dioxins, and poly-chlorinated biphenyls) (6,7). Hence, there is a need for an alternative source of omega-3 PUFAs.

Several alternative omega-3 PUFA products have been investigated. For example, transgenic oilseed crops and animals can produce an increase in the omega-6/omega-3 ratio of their fat. However, the use of genetically modified foods is highly controversial (6,8-11). Other alternative sources are microalgae, krill, and seal oil. Among these, microalgal oil is an attractive alternative for a substantial number of reasons. Microalgae, the common name for multiple single-cell, photogenic, heterotrophic, and mixotrophic organisms, have a high growth rate, short life cycle, and are less affected by environmental conditions such as season, location, and climate (6,12). Several species of microalgae can be stimulated for overproduction of a specific fatty acid, including EPA or DHA, through relative simple manipulations of their culture medium (13). Moreover, microalgal oil has better oxidative stability than fish oil (14) and thus some of the problems of fish oil can be avoided.

In this current study, microalgal oil was extracted from *Aurantiochytrium* sp. KRS101 (12). *Aurantiochytrium*

Received 8 September 2015; Accepted 4 December 2015; Published online 31 December 2015

Correspondence to Youn-Soo Cha, Tel: +82-63-270-3822, E-mail: cha8@jbnu.ac.kr

*These authors contributed equally to this work.

Copyright © 2015 by The Korean Society of Food Science and Nutrition. All rights Reserved.

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

sp. KRS101 is an oleaginous heterotrophic microalga found in the Malaysian mangrove ecosystem like soil, leaf and pneumatophore samples. These microalgae are capable of producing high quantity of lipid with DHA content over 45% of total fatty acid (12) which is safe for use in food and feed industries (15).

Many studies indicate that microalgal oils improve lipoprotein profiles; however these studies did not show any beneficial effect in terms of obesity (16-18). Therefore, this study was designed to investigate whether microalgal oil has beneficial effects against the development of high fat diet-induced obesity in rodents. Studies using C57BL/6J mice show that a high fat diet for 8 weeks will lead to significantly increased fat mass and plasma leptin levels (19). Therefore, after inducing obesity in C57BL/6J mice with a high fat diet, we then treated the mice orally with microalgal oil using an oral gavage and compared its effects to supplementation with other oils.

MATERIALS AND METHODS

Animals and diets

Male C57BL/6J mice, aged 6 weeks, were purchased from Charles River Laboratories (Tokyo, Japan). The animals were maintained on a pellet diet (Research Diets, New Brunswick, NJ, USA) for 1 week, and then randomly divided into 6 groups: normal diet with distilled water treatment group (ND), high fat diet with distilled water treatment group (HD), high fat diet with beef tallow treatment group (BT), high fat diet with corn oil treatment group (CO), high fat diet with fish oil treatment group (FO), and high fat diet with microalgal oil treatment group (MO). Before initiating the experiment, animals were fed with either a normal diet or a high fat diet for 8 weeks in order to induce obesity. After completion of the 8 week obesity-induction period, the animals were supplemented with distilled water, beef tallow, corn oil, fish oil, or microalgal oil for 8 weeks more. Beef tallow and corn oil were purchased from the Ottogi Company (Seoul, Korea). Microalgal oil was obtained from Korea Research Institute of Bioscience and Biotechnology (KRIBB, Jeongseup, Korea); the oil from the microalgae was extracted by using a previously reported method (12,15). The animals were housed in a temperature-controlled environment with a 12-h light/dark cycle and free access to food and water during the entire experimental period. The food intake was measured daily and body weight was measured weekly. The experimental protocol was approved by the Animal Care and Use Committee of Chonbuk National University (CBU 2012-0007).

Collection of serum and tissue samples

After a 12 h overnight fast, each mouse was deeply anesthetized using di-ethyl ether and blood was collected by orbital vein puncture. Blood samples were left on ice for 1 h, and then serum was collected from the clotted blood by centrifugation at 1,100 g for 15 min at 4°C (Micro 17R, Vision Scientific Co., Seoul, Korea). Serum samples were stored at -80°C until analysis. Tissues were surgically removed, weighed, and stored at -80°C until analysis.

Analysis of lipids

Hepatic lipids were extracted following the method previously described (20). Briefly, chloroform/methanol solution (2:1, v/v) was added to the homogenized liver tissues and the solution was vortexed and centrifuged. The lower phase was collected and evaporated at room temperature under a fume hood (Daihan Labtech Co., Ltd., Namyangju, Korea). The remaining semi-dried pellet was dissolved in 10 mL/L Triton X-100 (Yakuri Pure Chemicals Co., Ltd., Kyoto, Japan). The resulting solution was used to estimate hepatic triglyceride (TG) and total cholesterol (TC). Serum and hepatic TC and TG along with high density lipoprotein-cholesterol (HDL-c) were measured by an enzymatic method using a commercial kit (Asan Pharmaceutical Co., Seoul, Korea).

Quantitative real-time PCR analysis

Total RNA was extracted by TRIzol reagent and the concentration was measured spectrophotometrically (Shimadzu Corporation, Kyoto, Japan); the concentration of RNA was determined by absorbance at 260 nm and the quality of the RNA was determined by the ratio of signals at 260 nm to 280 nm. For real-time PCR, 1 µg of extracted RNA was reverse transcribed into first-stand cDNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Then, amplification was performed in a cDNA mixture on a 7500 Real Time PCR system (Applied Biosystems) and SYBER Green PCR Master Mix (Applied Biosystems, Woolston, Warrington, UK) according to the manufac-

Table 1. PCR primer sequences used for real-time PCR analysis

Gene		Primer sequence
PPAR-α	Forward	5'-CCT GAA CAT CGA GTG TCG AAT AT-3'
	Reverse	5'-GGT CTT CTT CTG AAT CTT GCA GCT-3'
CPT-1	Forward	5'-AAA GAT CAA TCG GAC CCT AGA CA-3'
	Reverse	5'-CAG GGA GTA GCG CAT AGT CA-3'
ACO	Forward	5'-CCA ACA TGA GGA CTA TAA CTT CCT-3'
	Reverse	5'-TAC ATA CGT GCC GTC AGG CTT-3'
SCD-1	Forward	5'-CAT CAT TCT CAT GGT CCT GCT-3'
	Reverse	5'-CCA GTC GTA CAC GTC ATT TT-3'
β-actin	Forward	5'-AGC CTT CCT TCT TGG GTA TGG-3'
	Reverse	5'-CAC TTG CGG TGC ACG GTA TGG-3'

turer's protocol. Relative quantification of gene expression with real-time PCR data was calculated relative to β -actin. The sequences of primers used in this study are given in Table 1.

Analyses of insulin and leptin

Serum insulin was measured using the insulin ELISA kit (SHIBAYAGI Co., Ltd., Shibukawa, Japan) and leptin concentrations were measured using the Quantikine® Immunoassay kit (R&D Systems, Minneapolis, MN, USA).

Statistical analysis

Data analysis was performed using SPSS version 16.0 (SPSS Institute, Chicago, IL, USA). Values are expressed as mean $\pm$ standard deviation. The statistical significance of differences between two groups was determined by Student's *t*-test. When significant differences were observed, mean values were compared with a one-way ANOVA among the groups. The differences among groups were assessed using Duncan's multiple range tests. Statistical significance was considered at $P < 0.05$.

RESULTS

Body weight and food intake

Table 2 shows that initial body weight did not differ significantly among the groups. After the 8 week run-in period to achieve diet-induced obesity, the body weight in all high fat feeding groups (i.e., HD, BT, CO, and MO) was significantly higher than the ND group. Similarly, the final body weight of mice in the HD group was significantly higher than that of the ND group. Although significant differences were not observed among the high fat groups, body weight gain was significantly dif-

ferent in the MO group compared to the HD group. During the pre-obesity induction period (0 wk to 8 wk), food intake (g/d) was significantly higher in the normal group, whereas energy intake (kcal/d) was significantly higher in the groups fed a high fat diet compared to the group fed a normal diet. In the post-obesity induction period (9 wk to 16 wk), food intake was significantly higher in the normal diet group compared to the high fat diet fed group; however, energy intake was not different among the groups (Table 2).

Epididymal fat pads

Epididymal fat pad weights (Fig. 1) were significantly higher in the groups consuming the high fat diet compared to the group consuming the normal diet. Among the groups consuming the high fat diet, the MO group showed significantly lower epididymal fat pad weights compared to the BT group. However, there was no sig-

Fig. 1. Epididymal fat weight. All values are mean $\pm$ SD. Values with different letters (a-c) are significantly different (ANOVA with Duncan's multiple range test at $P < 0.05$). ND, AIN-93 modified diet with 4% fat by weight (10% energy from fat); HD, AIN-93 modified high fat diet with 35% fat by weight (60% energy from fat); BT, high fat diet plus beef tallow; CO, high fat diet plus corn oil; FO, high fat diet plus fish oil; MO, high fat diet plus microalgal oil from *Aurantiochytrium* sp. KRS101.

Table 2. Body weight and food intake for the period during which obesity was induced and the experimental period

Groups	ND	HD	BT	CO	FO	MO
Initial body weight (g)	21.98 $\pm$ 0.86	21.93 $\pm$ 1.43	22.09 $\pm$ 1.02	22.42 $\pm$ 1.35	22.97 $\pm$ 1.25	22.61 $\pm$ 1.21
Body weight at 8 weeks (g)	29.19 $\pm$ 1.01 ^b	39.09 $\pm$ 3.11 ^a	38.45 $\pm$ 2.90 ^a	39.75 $\pm$ 3.38 ^a	39.01 $\pm$ 2.53 ^a	38.99 $\pm$ 2.76 ^a
Final body weight (g)	28.16 $\pm$ 0.96 ^c	41.58 $\pm$ 2.53 ^{ab}	43.88 $\pm$ 1.02 ^a	42.62 $\pm$ 1.31 ^a	41.50 $\pm$ 1.78 ^{ab}	39.94 $\pm$ 2.71 ^b
Body weight gain (g) ¹⁾	1.41 $\pm$ 1.17 ^d	3.37 $\pm$ 0.88 ^{ab}	3.84 $\pm$ 0.86 ^a	3.84 $\pm$ 0.86 ^{bc}	2.60 $\pm$ 1.68 ^{abc}	1.96 $\pm$ 0.72 ^{cd}
Food intake (g/d) ²⁾	2.64 $\pm$ 0.23 ^a	2.37 $\pm$ 0.02 ^b	2.32 $\pm$ 0.05 ^b	2.29 $\pm$ 0.07 ^b	2.30 $\pm$ 0.02 ^b	2.24 $\pm$ 0.10 ^b
Energy intake (kcal/d) ²⁾	10.29 $\pm$ 0.89 ^b	12.33 $\pm$ 0.08 ^a	12.05 $\pm$ 0.25 ^a	11.89 $\pm$ 0.34 ^a	11.98 $\pm$ 0.10 ^a	11.65 $\pm$ 0.50 ^a
Food intake (g/d) ³⁾	2.77 $\pm$ 0.04 ^a	2.07 $\pm$ 0.03 ^b	2.03 $\pm$ 0.13 ^b	1.89 $\pm$ 0.08 ^b	1.91 $\pm$ 0.10 ^b	1.89 $\pm$ 0.78 ^b
Energy intake (kcal/d) ³⁾	10.81 $\pm$ 0.15	10.78 $\pm$ 0.15	10.55 $\pm$ 0.66	9.84 $\pm$ 0.40	9.91 $\pm$ 0.50	9.85 $\pm$ 0.40

All values are mean $\pm$ SD.

Values with different letters (a-d) within the same row are significantly different (ANOVA with Duncan's multiple range test at $P < 0.05$).

ND, AIN-93 modified diet with 4% fat by weight (10% energy from fat); HD, AIN-93 modified high fat diet with 35% fat by weight (60% energy from fat); BT, high fat diet plus beef tallow; CO, high fat diet plus corn oil; FO, high fat diet plus fish oil; MO, high fat diet plus microalgal oil from *Aurantiochytrium* sp. KRS101.

¹⁾Body weight gain during experimental period.

²⁾For the obesity induction period.

³⁾For the experimental period.

nificant difference observed between the MO and HD groups.

Lipid concentrations in serum and liver

The effects of omega-3 PUFAs on hepatic and serum lipid profiles are described as following. The concentrations of hepatic TG and TC were significantly lower in the MO group compared to the HD, BT, and CO groups (Fig. 2A and B). As for the serum lipid profiles, serum TG was significantly lower in both the FO and MO groups compared to the HD group (Fig. 3A). Serum TC was significantly lower in the MO group compared to the BT and CO groups (Fig. 3B). The ratio of HDL-c to

TC was significantly higher in the FO and MO groups compared to BT and CO groups (Fig. 3C).

Hepatic mRNA levels

The expression level of genes involved in hepatic lipid metabolism is shown in Fig. 4. Peroxisome proliferator-activated receptor (PPAR)- α is a gene involved in lipid catabolism. It regulates the expression of carnitine palmitoyltransferase (CPT)-1 and acyl-CoA oxidase (ACO), which are involved in β -oxidation of lipids in the mitochondria and the peroxisomes, respectively. Although the expression pattern of all three genes remained similar, there was a small but significantly higher expres-

Fig. 2. Lipid concentrations of triglyceride (A) and total cholesterol (B) in liver. All values are mean $\pm$ SD. Values with different letters (a-c) are significantly different (ANOVA with Duncan's multiple range test at $P < 0.05$). ND, AIN-93 modified diet with 4% fat by weight (10% energy from fat); HD, AIN-93 modified high fat diet with 35% fat by weight (60% energy from fat); BT, high fat diet plus beef tallow; CO, high fat diet plus corn oil; FO, high fat diet plus fish oil; MO, high fat diet plus microalgal oil from *Aurantiochytrium* sp. KRS101.

Fig. 3. Lipid concentrations of triglyceride (A) and total cholesterol (B), and HDL-c (high density lipoprotein)/TC (total cholesterol) (C) in serum. All values are mean $\pm$ SD. Values with different letters (a-d) are significantly different (ANOVA with Duncan's multiple range test at $P < 0.05$). ND, AIN-93 modified diet with 4% fat by weight (10% energy from fat); HD, AIN-93 modified high fat diet with 35% fat by weight (60% energy from fat); BT, high fat diet plus beef tallow; CO, high fat diet plus corn oil; FO, high fat diet plus fish oil; MO, high fat diet plus microalgal oil from *Aurantiochytrium* sp. KRS101.

Fig. 4. mRNA levels of PPAR- α (A), CPT-1 (B), ACO (C), and SCD-1 (D) in liver. All values are mean $\pm$ SD. Values with different letters (a-d) are significantly different (ANOVA with Duncan's multiple range test at $P < 0.05$). ND, AIN-93 modified diet with 4% fat by weight (10% energy from fat); HD, AIN-93 modified high fat diet with 35% fat by weight (60% energy from fat); BT, high fat diet plus beef tallow; CO, high fat diet plus corn oil; FO, high fat diet plus fish oil; MO, high fat diet plus microalgal oil from *Aurantiochytrium* sp. KRS101.

Fig. 5. Insulin (A) and leptin (B) concentrations in serum. All values are mean $\pm$ SD. Values with different letters (a-d) are significantly different (ANOVA with Duncan's multiple range test at $P < 0.05$). ND, AIN-93 modified diet with 4% fat by weight (10% energy from fat); HD, AIN-93 modified high fat diet with 35% fat by weight (60% energy from fat); BT, high fat diet plus beef tallow; CO, high fat diet plus corn oil; FO, high fat diet plus fish oil; MO, high fat diet plus microalgal oil from *Aurantiochytrium* sp. KRS101.

sion of PPAR- α and ACO in the MO and FO groups compared to the HD group (Fig. 4A-C). At the same time, the BT, CO, HD, and ND groups showed a similar expression level of all three genes. The lipid anabolic gene, stearoyl-CoA desaturase enzyme (SCD)-1, is involved in lipogenesis. It showed significantly lower expression in the MO and FO groups compared to the HD and BT groups (Fig. 4D).

Insulin and leptin levels in serum

As shown in Fig. 5A and B, the levels of serum insulin and leptin were significantly higher in the HD group compared with the ND group. Supplementation with MO significantly reduced the rise in serum insulin and leptin compared to other groups consuming the high fat diet.

DISCUSSION

Many studies on humans and animals have demonstrated the beneficial effects of omega-3 PUFAs from fish oil (4,5). Hence, it is well known that omega-3 PUFAs improve serum lipid levels and are beneficial against obesity. Specifically, omega-3 PUFAs differ from other fatty acids in relation to their storage as triglycerides in mature adipocytes. An excess of triglyceride storage promotes hyperplasia and hypertrophy of adipocytes leading to obesity, (21) and omega-3 PUFAs, especially EPA and DHA, can inhibit adipocyte hypertrophy and decrease the lipid content of adipose tissue (22).

Earlier reports on microalgal oil suggested it could be an alternative to omega-3 fish oils; however, most of these studies failed to observe any significant differences in obesity-related markers other than changes in the serum lipid profiles. Therefore, in order to gain insight into the benefits of microalgal oil, we induced obesity in mice by feeding them a high fat diet for 8 weeks, followed by supplementation with different oils (along with the same high fat diet) for 8 more weeks. Since the energy demand changes due to the estrous cycle in female mice, leading to variations in food intake, we used male mice in this current study (23-26). The anti-obesity effects of the microalgal oil supplementation were quantified in high-fat diet-induced obese C57BL/6J mice by assessing body weight changes, body fat pad weights, serum and hepatic lipid profiles, serum insulin and leptin concentrations, and changes in hepatic mRNA levels related to lipid metabolism. Since fish oil is a common omega-3 fatty acid supplement, it was used as a positive control; beef tallow, rich in saturated fatty acids, and corn oil, a good source of omega-6 fatty acids, served as negative controls.

We observed that oil from the microalgae *Aurantiochytrium* sp. KRS101, which is rich in long chain omega-3 fatty acids, was effective against further weight gain in diet-induced obese mice compared to beef tallow or corn oil. The treatment of the obese animals with MO for a period of 8 weeks caused a decrease in the rate of weight gain compared to the other groups in the high fat diet regimen; this was true despite significant differences in food intake. We also found that animals treated with either omega-3 fatty acid source (i.e., FO or MO oil) had less epididymal adipose tissue compared to those in the HD, BT, and CO groups.

Dietary omega-3 fatty acids are regarded as down regulators of anabolic lipid genes and activators of catabolic lipid genes. Specifically, omega-3s have been shown to activate PPAR- α (27), which belongs to a superfamily of steroid nuclear receptors and plays a crucial role in regulating lipid homeostasis (4). In addition, PPAR- α activation leads to the induction of genes encoding for pro-

teins involved in lipid transport and oxidation including CPT-1 and ACO (28). CPT-1 and ACO are rate-limiting enzymes involved in mitochondrial and peroxisomal β -oxidation, respectively (29,30). In addition, SCD-1 is a lipogenic enzyme involved in the biosynthesis of cholesterol and triglyceride in the liver (31-33). Higher expression of hepatic SCD-1 promotes lipogenesis and formation of hepatic lipid droplets (31). In a study with SCD-1 knockout mice, a higher expression of PPAR- α , CPT-1, and ACO was observed. Consequently, there was an increase in lipid oxidation and an enhanced availability of free fatty acids for mitochondrial β -oxidation, thereby reducing TG synthesis and storage (34). Similarly, in our study the mRNA expression levels of PPAR- α , CPT-1, and ACO were significantly higher and the expression of SCD-1 was significantly lower in the FO and MO groups compared to the HD and BT groups. This observation suggests that the omega-3 fatty acid-rich microalgal and fish oils were effective at lowering triglyceride and cholesterol synthesis and accumulation in the liver. Also, a higher HDL-c/TC ratio and lower level of serum TG and TC were also observed in the group supplemented with MO compared to the other groups. These results suggest that microalgal oil has hypocholesterolemic and hypolipidemic properties.

Consuming a high fat diet causes hyperinsulinemia (35) as a result of the rise in adiposity (36). PPAR- α activation has been shown to improve insulin sensitivity by lowering the circulating lipids and lowering adiposity (37). In our study, one of the reasons that serum insulin was lower in the MO group could be due to the activation of PPAR- α and improvement of insulin sensitivity by omega 3-fatty acids. Supporting our study, other reports have also indicated that higher intakes of dietary omega-3 fatty acids improve insulin sensitivity (38,39). Leptin is an adipokine secreted by adipose tissue. It was reported that epididymal adipose tissue secretes the highest quantity of leptin compared to adipose tissues depots (40). Moreover, circulating leptin concentrations are proportional to the amount of adipose tissue mass (41). In this current study, a lower level of epididymal adipose tissue was observed in the MO and FO supplemented groups compared to the other groups fed a high fat diet. Therefore, it could be possible that a lower circulatory leptin level in the MO and FO groups could be a result of the lower amount of epididymal adipose mass in these groups. Moreover, serum insulin and leptin showed a similar tendency, suggesting that the beneficial effects of microalgal oil against hyperinsulinemia and hyperleptinemia could be attributable to the protective effects against obesity. In conclusion, our results demonstrated that oil from microalgae *Aurantiochytrium* sp. KRS101 had beneficial effects against high fat diet-induced obesity. Regular supplementation of microalgal

oil in obese rodents significantly up-regulated the mRNA expression of genes related to lipid catabolism (i.e., CPT-1, ACO, and PPAR- α) while lowering the expression of a lipid anabolic gene (SCD-1). The change in the expression pattern of lipid metabolic genes resulted in a significant decrease in serum hyperlipidemia along with a reduction in hepatic lipids. Moreover, epididymal adipose tissue mass was significantly decreased as a result of microalgal oil intake, and this result was reflected in lower levels of serum leptin and insulin. Microalgal oil supplementation, rich in omega-3 fatty acids, has anti-obesity actions; however, appropriate human studies must be conducted to explore its use as an alternative to fish oil for the purpose of controlling obesity.

AUTHOR DISCLOSURE STATEMENT

The authors declare no conflict of interest.

REFERENCES

1. Yamanushi TT, Kabuto H, Hirakawa E, Janjua N, Takayama F, Mankura M. 2014. Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats. *J Nutr* 144: 467-474.
2. Yang P, Cartwright C, Chan D, Ding J, Felix E, Pan Y, Pang J, Rhea P, Block K, Fischer SM, Newman RA. 2014. Anticancer activity of fish oils against human lung cancer is associated with changes in formation of PGE₂ and PGE₃ and alteration of Akt phosphorylation. *Mol Carcinog* 53: 566-577.
3. Brown AL, Zhu X, Rong S, Shewale S, Seo J, Boudyguina E, Gebre AK, Alexander-Miller MA, Parks JS. 2012. Omega-3 fatty acids ameliorate atherosclerosis by favorably altering monocyte subsets and limiting monocyte recruitment to aortic lesions. *Arterioscler Thromb Vasc Biol* 32: 2122-2130.
4. Fiamoncini J, Turner N, Hirabara SM, Salgado TM, Marçal AC, Leslie S, da Silva SM, Deschamps FC, Luz J, Cooney GJ, Curi R. 2013. Enhanced peroxisomal β -oxidation is associated with prevention of obesity and glucose intolerance by fish oil-enriched diets. *Obesity* 21: 1200-1207.
5. Simopoulos AP. 2008. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp Biol Med* 233: 674-688.
6. Martins DA, Custódio L, Barreira L, Pereira H, Ben-Hamadou R, Varela J, Abu-Salah KM. 2013. Alternative sources of n-3 long-chain polyunsaturated fatty acids in marine microalgae. *Mar Drugs* 11: 2259-2281.
7. Tur JA, Bibiloni MM, Sureda A, Pons A. 2012. Dietary sources of omega 3 fatty acids: public health risks and benefits. *Br J Nutr* 107: S23-S52.
8. Meesapyodsuk D, Qiu X. 2012. The front-end desaturase: structure, function, evolution and biotechnological use. *Lipids* 47: 227-237.
9. Sayanova O, Napier JA. 2011. Transgenic oilseed crops as an alternative to fish oils. *Prostaglandins Leukot Essent Fatty Acids* 85: 253-260.
10. Wu X, Ouyang H, Duan B, Pang D, Zhang L, Yuan T, Xue L, Ni D, Cheng L, Dong S, Wei Z, Li L, Yu M, Sun QY, Chen DY, Lai L, Dai Y, Li GP. 2012. Production of cloned transgenic cow expressing omega-3 fatty acids. *Transgenic Res* 21: 537-543.
11. Zhang P, Zhang Y, Dou H, Yin J, Chen Y, Pang X, Vajta G, Bolund L, Du Y, Ma RZ. 2012. Handmade cloned transgenic piglets expressing the nematode *fat-1* gene. *Cell Reprogram* 14: 258-266.
12. Hong WK, Rairakhwada D, Seo PS, Park SY, Hur BK, Kim CH, Seo JW. 2011. Production of lipids containing high levels of docosahexaenoic acid by a newly isolated microalga, *Aurantiochytrium* sp. KRS101. *Appl Biochem Biotechnol* 164: 1468-1480.
13. Perez-Garcia O, Escalante FM, de-Bashan LE, Bashan Y. 2011. Heterotrophic cultures of microalgae: metabolism and potential products. *Water Res* 45: 11-36.
14. Ryckebosch E, Bruneel C, Termote-Verhalle R, Lemahieu C, Muylaert K, Van Durme J, Goiris K, Foubert I. 2013. Stability of omega-3 LC-PUFA-rich photoautotrophic microalgal oils compared to commercially available omega-3 LC-PUFA oils. *J Agric Food Chem* 61: 10145-10155.
15. Hong WK, Yu A, Oh BR, Park JM, Kim CH, Sohn JH, Kondo A, Seo JW. 2013. Large-scale production of microalgal lipids containing high levels of docosahexaenoic acid upon fermentation of *Aurantiochytrium* sp. KRS101. *Food Nutr Sci* 4: 1-5.
16. Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL. 2011. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. *J Nutr* 141: 207-213.
17. Geppert J, Kraft V, Demmelmair H, Koletzko B. 2006. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. *Br J Nutr* 95: 779-786.
18. Sanders TA, Gleason K, Griffin B, Miller GJ. 2006. Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. *Br J Nutr* 95: 525-531.
19. Lin S, Thomas TC, Storlien LH, Huang XF. 2000. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. *Int J Obes* 24: 639-646.
20. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* 37: 911-917.
21. Azain MJ. 2004. Role of fatty acids in adipocyte growth and development. *J Anim Sci* 82: 916-924.
22. Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Veck M, Trzicka E, Bryhn M, Kopecky J. 2004. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. *Lipids* 39: 1177-1185.
23. Wade GN. 1972. Gonadal hormones and behavioral regulation of body weight. *Physiol Behav* 8: 523-534.
24. Czaja JA, Goy RW. 1975. Ovarian hormones and food intake in female guinea pigs and rhesus monkeys. *Horm Behav* 6: 329-349.
25. Czaja JA. 1975. Food rejection by female rhesus monkeys during the menstrual cycle and early pregnancy. *Physiol Behav* 14: 579-587.
26. Czaja JA. 1978. Ovarian influences on primate food intake: assessment of progesterone actions. *Physiol Behav* 21: 923-928.
27. Jump DB. 2008. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. *Curr Opin Lipidol* 19: 242-247.
28. Sampath H, Ntambi JM. 2004. Polyunsaturated fatty acid regulation of gene expression. *Nutr Rev* 62: 333-339.
29. McGarry JD, Leatherman GF, Foster DW. 1978. Carnitine palmitoyltransferase I—the site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. *J Biol Chem* 253: 4128-4136.
30. Miyazawa S, Hayashi H, Hijikata M, Ishii N, Furuta S,

- Kagamiyama H, Osumi T, Hashimoto T. 1987. Complete nucleotide sequence of cDNA and predicted amino acid sequence of rat acyl-CoA oxidase. *J Biol Chem* 262: 8131-8137.
31. Yee JK, Wahjudi PN, Vega J, Lim S, Martin A, Patterson ME, Cohen JN, Mao CS, Lee WN. 2013. Stearoyl-CoA desaturase enzyme 1 inhibition reduces glucose utilization for de novo fatty acid synthesis and cell proliferation in 3T3-L1 adipocytes. *Metabolomics* 9: 809-816.
 32. Lu RH, Liang XF, Wang M, Zhou Y, Bai XL, He Y. 2012. The role of leptin in lipid metabolism in fatty degenerated hepatocytes of the grass carp *Ctenopharyngodon idellus*. *Fish Physiol Biochem* 38: 1759-1774.
 33. Fernández Gianotti T, Burgueño A, Gonzales Mansilla N, Pirola CJ, Sookoian S. 2013. Fatty liver is associated with transcriptional downregulation of stearoyl-CoA desaturase and impaired protein dimerization. *PLoS One* 8: e76912.
 34. Ntambi JM, Miyazaki M, Stoeckl JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. *Proc Natl Acad Sci USA* 99: 11482-11486.
 35. Barnard RJ, Roberts CK, Varon SM, Berger JJ. 1998. Diet-induced insulin resistance precedes other aspects of the metabolic syndrome. *J Appl Physiol* 84: 1311-1315.
 36. Gale SM, Castracane VD, Mantzoros CS. 2004. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. *J Nutr* 134: 295-298.
 37. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. 2005. Peroxisome proliferator-activated receptor (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPAR α , PPAR γ , and their combination. *Diabetes* 54: 3358-3370.
 38. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. 2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell* 142: 687-698.
 39. Hofacer R, Magrisso JJ, Jandacek R, Rider T, Tso P, Benoit SC, McNamara RK. 2012. Omega-3 fatty acid deficiency increases stearoyl-CoA desaturase expression and activity indices in rat liver: positive association with non-fasting plasma triglyceride levels. *Prostaglandins Leukot Essent Fatty Acids* 86: 71-77.
 40. Nazian SJ. 2001. Leptin secretion from the epididymal fat pad is increased by the sexual maturation of the male rat. *J Androl* 22: 491-496.
 41. Barr VA, Malide D, Zarnowski MJ, Taylor SI, Cushman SW. 1997. Insulin stimulates both leptin secretion and production by rat white adipose tissue. *Endocrinology* 138: 4463-4472.